These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17713023)

  • 1. Tumor cell vaccines.
    Thompson PL; Dessureault S
    Adv Exp Med Biol; 2007; 601():345-55. PubMed ID: 17713023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell technologies in immunotherapy of cancer.
    Moiseyenko V; Imyanitov E; Danilova A; Danilov A; Baldueva I
    Adv Exp Med Biol; 2007; 601():387-93. PubMed ID: 17713028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines.
    Chekhun VF
    Exp Oncol; 2008 Jun; 30(2):90. PubMed ID: 18680872
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of tumor cell-based vaccines.
    Copier J; Dalgleish A
    Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic cancer vaccines: From initial findings to prospects.
    Song Q; Zhang CD; Wu XH
    Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous versus allogeneic cell-based vaccines?
    Parmiani G; Pilla L; Maccalli C; Russo V
    Cancer J; 2011; 17(5):331-6. PubMed ID: 21952283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New strategies in cancer immunotherapy].
    Ruan RS; Xu KC
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):943-6. PubMed ID: 22340107
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of optimized cryptic peptides for immunotherapy.
    Menez-Jamet J; Kosmatopoulos K
    IDrugs; 2009 Feb; 12(2):98-102. PubMed ID: 19204883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
    Ikeda H; Shiku H
    Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
    Fournier P; Schirrmacher V
    Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.
    Speiser DE; Romero P
    Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new twist on autologous cancer vaccines.
    Emens LA
    Cancer Biol Ther; 2003; 2(2):161-3. PubMed ID: 12750555
    [No Abstract]   [Full Text] [Related]  

  • 17. The cyclins: a family of widely expressed tumor antigens?
    von Bergwelt-Baildon MS; Kondo E; Klein-González N; Wendtner CM
    Expert Rev Vaccines; 2011 Mar; 10(3):389-95. PubMed ID: 21434806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?
    Zöller M
    Technol Cancer Res Treat; 2003 Jun; 2(3):237-60. PubMed ID: 12779354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.